Results 271 to 280 of about 112,622 (301)
Some of the next articles are maybe not open access.
PARP inhibitors for cancer therapy
Expert Reviews in Molecular Medicine, 2005Poly(ADP-ribose) polymerase 1 (PARP-1) is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks. Poly(ADP-ribosyl)ation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that activate either DNA repair by the base-excision pathway or cell death. A family of 18 PARPs has been identified, but only the most
openaire +3 more sources
The Vasoactivity of PARP Inhibitors
2015PARP-inhibition has proven to be an attractive therapeutic approach in cancer whereby the effectiveness of DNA-damaging therapy can be enhanced by inhibiting the PARP-mediated DNA-repair process. Generally there is good concordance between enhanced therapeutic efficacy in vitro and that observed in vivo.
Williams, Kaye J., McCrudden, Cian M.
openaire +2 more sources
PARP inhibitors in ovarian cancer
Seminars in OncologyPoly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency.
Ian S. Goldlust +2 more
openaire +2 more sources
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Nature Reviews Clinical Oncology, 2021Mariana Paes Dias +2 more
exaly
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Nature Reviews Clinical Oncology, 2021Eapm Working Group For Oncology Clinical Research +2 more
exaly
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Ca-A Cancer Journal for Clinicians, 2011Timothy A Yap, Johann Sebastian de Bono
exaly
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Ca-A Cancer Journal for Clinicians, 2019Stephanie Lheureux +2 more
exaly